ORF1p nanoplasmid DNA vaccine

The ORF1p nanoplasmid DNA vaccine is an antibiotic-free DNA-based immunotherapy designed to target the Open Reading Frame 1 protein (ORF1p) of the LINE-1 (Long Interspersed Nuclear Element-1) retrotransposon. LINE-1 ORF1p is frequently overexpressed in various cancers, including early-onset colorectal cancer, and is associated with aging and tumor progression. The vaccine utilizes a nanoplasmid vector and is delivered via intramuscular electroporation (specifically using Ichor's TriGrid™ technology) to induce an immune response against ORF1p-expressing cells. In preclinical models, the vaccine has demonstrated the ability to delay tumor onset and inhibit tumor growth, suggesting potential applications in both cancer prevention and treatment.

Other names

LINE1 ORF1p DNA vaccineLINE-1 ORF1p DNA vaccineLINE 1 ORF1p DNA vaccineantibiotic-free nanoplasmid DNA vaccine targeting ORF1p